Sophia Shalhout PhD joined the Miller Lab as the Cutaneous Oncology Research Fellow in 2019. She obtained her Ph.D. in Chemistry from Wayne State University where she studied the role of activation-induced deaminase (AID) in promoting lymphoma, and developed tools to study and quantify the type of DNA damage caused by aberrant AID activity. The exploitation of AID-induced DNA damage led to the development of small molecule chemical probes to specifically target lymphoma cells.
She then did a postdoctoral fellowship at Boston Children’s Hospital in the Camargo lab, where she worked to develop novel small molecule modulators of the Hippo Pathway for applications in both regenerative medicine and chemotherapy.
Dr. Shalhout is currently using her skills in Biology and Data Science in the Miller Lab to identify biomarkers of response to therapies for Merkel cell carcinoma.
B.S in Chemistry and Biological Sciences, 2009
Wayne State University
PhD in Chemistry, 2015
Wayne State University
Post-Doctoral Fellowship, 2015-2019
Boston Children's Hospital, Harvard Medical School
Introduction to RNA-Seq, 2015
Harvard Chan Bioinformatics Core, Harvard School of Public Health
In-depth Next Generation Sequencing analysis, 2016
Harvard Chan Bioinformatics Core, Harvard School of Public Health
Introduction to single-cell RNA-seq data analysis, 2019
Harvard Chan Bioinformatics Core, Harvard School of Public Health
Introduction to Differential Gene Expression Analysis, 2019
Harvard Chan Bioinformatics Core, Harvard School of Public Health
Bulk RNA-seq Analysis, 2020
Harvard Chan Bioinformatics Core, Harvard School of Public Health
Certificate in Applied Biostatistics, 2020
Harvard Catalyst | The Harvard Clinical and Translational Science Center, Harvard Medical School